Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
399 studies found for:    "Myelofibrosis"
Show Display Options
Rank Status Study
21 Unknown  Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: arsenic trioxide;   Drug: cytarabine
22 Completed Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Procedure: Allogeneic Stem Cell Transplantation
23 Recruiting Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Condition: Myelofibrosis
Interventions: Drug: Ruxolotinib;   Drug: peg-IFN alpha -2a
24 Terminated
Has Results
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib
25 Completed A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
Conditions: Myelofibrosis;   Myeloid Metaplasia
Intervention: Drug: zoledronic acid
26 Completed Thalidomide in Treating Patients With Myelofibrosis
Condition: Primary Myelofibrosis
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
27 Active, not recruiting A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INC424;   Drug: BKM120
28 Completed
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
29 Completed
Has Results
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Condition: Myelofibrosis
Interventions: Drug: INC424/INCB018424;   Drug: Best Available Therapy (BAT)
30 Active, not recruiting
Has Results
Decitabine in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis
31 Recruiting P1101 in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Other: Laboratory Biomarker Analysis;   Biological: PEG-Proline-Interferon Alfa-2b;   Other: Quality-of-Life Assessment
32 Completed A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: TG101348
33 Completed Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Condition: Myelofibrosis
Intervention: Drug: Obatoclax mesylate (GX15-070MS)
34 Withdrawn A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
Condition: Primary Myelofibrosis
Intervention: Biological: Pacritinib
35 Recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
36 Recruiting Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Condition: Early Myelofibrosis With High Molecular Risk Mutations
Interventions: Drug: Ruxolitinib;   Drug: Ruxolitinib Placebo
37 Active, not recruiting
Has Results
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide 0.5 mg;   Drug: Placebo
38 Recruiting Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
39 Recruiting JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
40 Completed
Has Results
CEP-701 for PH-negative Myelofibrosis
Conditions: Leukemia;   Myelofibrosis
Intervention: Drug: CEP-701

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.